Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
31
ARTV Quote, Financials, Valuation and Earnings
Last price:
$11.13
Seasonality move
:
--
Day range:
$9.68 - $11.41
52-week range:
$9.68 - $17.31
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
48.72x
P/B ratio:
--
Volume:
352.8K
Avg. volume:
60.4K
1-year change:
--
Market cap:
$195.4M
Revenue:
$33.5M
EPS (TTM):
-$3.08
Analysts' Opinion
-
Consensus RatingArtiva Biotherapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Artiva Biotherapeutics has an estimated upside of 91.27% from its current price of $11.11.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $11.11.
Fair Value
-
According to the consensus of 0 analysts, Artiva Biotherapeutics has 91.27% upside to fair value with a price target of -- per share.
ARTV vs. S&P 500
-
Over the past 5 trading days, Artiva Biotherapeutics has overperformed the S&P 500 by 6.74% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Artiva Biotherapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Artiva Biotherapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Artiva Biotherapeutics reported revenues of $251K.
Earnings Growth
-
Artiva Biotherapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Artiva Biotherapeutics reported earnings per share of -$0.79.
Enterprise value:
133.2M
EV / Invested capital:
--
Price / LTM sales:
48.72x
EV / EBIT:
--
EV / Revenue:
33.22x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-2.64x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-38.54%
Net Income Margin (TTM):
-1351.52%
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
-5773.71%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2023-03-31 | 2024-03-31 | |
| Income Statement | ||||||
| Revenue | -- | $3.9M | $4M | $989K | $251K | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$53.8M | -$65.4M | -$55.7M | -$17.7M | -$14.5M | |
| EBITDA | -$53.3M | -$64.5M | -$54.2M | -$17.1M | -$13.9M | |
| Diluted EPS | -$4.10 | -$4.72 | -$3.08 | -$0.95 | -$0.79 | |
| Period Ending | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $153.2M | -- | $65.9M | |
| Total Assets | -- | -- | $161.8M | -- | $90.2M | |
| Current Liabilities | -- | -- | $22.6M | -- | $10.4M | |
| Total Liabilities | -- | -- | $261.2M | -- | $264.8M | |
| Total Equity | -- | -- | -$99.4M | -- | -$174.7M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2023-03-31 | 2024-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -$14.2M | -$15.1M | |
| Cash From Investing | -- | -- | -- | -$1.9M | $9.8M | |
| Cash From Financing | -- | -- | -- | -$12K | -- | |
| Free Cash Flow | -$20.7M | -$26.9M | -$50.5M | -$16.1M | -$15.1M | |
ARTV
Sector
Market Cap
$195.4M
$44.6M
Price % of 52-Week High
64.18%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.68%
1-Year Price Total Return
--
-29.09%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$10.68
200-day SMA
Buy
Level
$0.00
Bollinger Bands (100)
Sell
Level
10.35 - 13.41
Chaikin Money Flow
Buy
Level
3.1M
20-day SMA
Sell
Level
$11.58
Relative Strength Index (RSI14)
Sell
Level
47.90
ADX Line
Buy
Level
4.55
Williams %R
Neutral
Level
-58.6705
50-day SMA
Sell
Level
$11.71
MACD (12, 26)
Sell
Level
-0.38
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Neutral
Level
3.3M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
Sell
CA Score
(Annual)
Level (-9.6475)
--
Beneish M-Score
(Annual)
Level (--)
--
Momentum Score
Level (--)
Sell
Ohlson Score
Level (14.2934)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials.
Stock Forecast FAQ
In the current month, ARTV has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ARTV average analyst price target in the past 3 months is --.
-
Where Will Artiva Biotherapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Artiva Biotherapeutics share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Artiva Biotherapeutics?
Analysts are divided on their view about Artiva Biotherapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Artiva Biotherapeutics is a Sell and believe this share price will drop from its current level to --.
-
What Is Artiva Biotherapeutics's Price Target?
The price target for Artiva Biotherapeutics over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ARTV A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Artiva Biotherapeutics is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ARTV?
You can purchase shares of Artiva Biotherapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Artiva Biotherapeutics shares.
-
What Is The Artiva Biotherapeutics Share Price Today?
Artiva Biotherapeutics was last trading at $11.13 per share. This represents the most recent stock quote for Artiva Biotherapeutics. Yesterday, Artiva Biotherapeutics closed at $11.11 per share.
-
How To Buy Artiva Biotherapeutics Stock Online?
In order to purchase Artiva Biotherapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
